A Paris biopharma leader in gene therapy, utilizing AI in Feb 2026.nnKey FeaturesnUses optogenetics and mitochondrial targeting to treat rare blinding diseases, with production optimized by AI-driven tech transfers.nnUse CasenCurrently in Phase III trials (RECOVER), using AI to analyze patient response data for treating Leber Hereditary Optic Neuropathy.nnWhy Choose GenSight?nIt represents the cutting edge of ‘French Biotech,’ combining AI-driven clinical research with revolutionary gene-editing technology.